Literature DB >> 1936057

Tissue distribution of propafenone in the rat after intravenous administration.

J Fernández1, L Lligoña, A Puigdemont, R Guitart, J L Riu, M Arboix.   

Abstract

Tissue distribution of propafenone has been studied in the rat. Measurement of propafenone was made in several tissues: plasma, heart, kidney, lung, liver, muscle, fat and brain, after i.v. administration of 2 mg/kg of the drug. The plasma propafenone kinetics profile can be described by a two-compartmental model. The pharmacokinetic parameters, derived from plasma levels, showed a t1/2 beta of 55.4 min, the central Vd/kg of 2.4 ml/kg, the Cl of 62.8 ml/min.kg and the AUC0-oo of 31.6 micrograms.min/ml. The analysis of the propafenone tissue distribution showed the highest concentration of drug in the lung, followed by the heart and kidneys. A significant concentration was found in brain, muscle and adipose tissue, with concentration ratios (tissue/plasma) above 1. The half-life values obtained for individual organs and tissues are similar to those obtained in plasma, around 1 h. In the post-distributive phase, plasma and tissue concentrations decline in parallel.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1936057     DOI: 10.1007/BF03189870

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  20 in total

1.  Distribution of propafenone and its active metabolite, 5-hydroxypropafenone, in human tissues.

Authors:  R Latini; S Marchi; E Riva; A Cavalli; M G Cazzaniga; A P Maggioni; A Volpi
Journal:  Am Heart J       Date:  1987-03       Impact factor: 4.749

2.  [Plasma level and effectiveness of propafenone and its organ distribution (author's transl)].

Authors:  H Blanke; B Aschbrenner; K R Karsch; H Kreuzer
Journal:  Dtsch Med Wochenschr       Date:  1979-04-20       Impact factor: 0.628

Review 3.  Propafenone--a new antiarrhythmic drug.

Authors:  L Seipel; G Breithardt
Journal:  Eur Heart J       Date:  1980-08       Impact factor: 29.983

4.  Statistical moments in pharmacokinetics.

Authors:  K Yamaoka; T Nakagawa; T Uno
Journal:  J Pharmacokinet Biopharm       Date:  1978-12

5.  Suppression of ventricular arrhythmias by propafenone, a new antiarrhythmic agent, during acute myocardial infarction in the conscious dog. A comparative study with lidocaine.

Authors:  H S Karagueuzian; T Fujimoto; T Katoh; T Peter; A McCullen; W J Mandel
Journal:  Circulation       Date:  1982-12       Impact factor: 29.690

6.  Determination of plasma protein binding of propafenone in rats, dogs and humans by highly sensitive gas chromatography-mass spectrometry.

Authors:  S Higuchi; C Urano; S Kawamura
Journal:  J Chromatogr       Date:  1985-06-14

7.  Clinical pharmacology of propafenone.

Authors:  S J Connolly; R E Kates; C S Lebsack; D C Harrison; R A Winkle
Journal:  Circulation       Date:  1983-09       Impact factor: 29.690

8.  Propafenone disposition kinetics in cardiac arrhythmia.

Authors:  S Connolly; C Lebsack; R A Winkle; D C Harrison; R E Kates
Journal:  Clin Pharmacol Ther       Date:  1984-08       Impact factor: 6.875

9.  Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences.

Authors:  L A Siddoway; K A Thompson; C B McAllister; T Wang; G R Wilkinson; D M Roden; R L Woosley
Journal:  Circulation       Date:  1987-04       Impact factor: 29.690

10.  Pharmacokinetics of intravenous propafenone in patients with episodes of paroxysmal supraventricular tachycardia.

Authors:  M Arboix; A Puigdemont; A Moya; J Cinca
Journal:  Methods Find Exp Clin Pharmacol       Date:  1985-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.